Physician profile
Shiny Joseph
NPI 1801652151
$1,813.87
in general payments reported to CMS, 2019-2025
31 companies · $1,814 in 2025
The $1,814 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.88 |
| Education | $293.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $170.59 | 2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $151.44 | 2025 | Keytruda, Welireg, Lynparza |
| Gilead Sciences, INC. | $151.14 | 2025 | Trodelvy |
| Astellas Pharma US INC | $145.38 | 2025 | Vyloy, Xtandi |
| Stemline Therapeutics INC. | $125.00 | 2025 | Orserdu |
| Astrazeneca Pharmaceuticals LP | $106.40 | 2025 | Imfinzi |
| Seagen INC. | $99.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $91.19 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.76 | 2025 | |
| Caris Mpi, INC. | $56.59 | 2025 | Mi Cancer Seek |
| Regeneron Healthcare Solutions, INC. | $54.89 | 2025 | Libtayo |
| Geron Corporation | $50.58 | 2025 | Rytelo |
| Genentech USA, INC. | $45.14 | 2025 | Tecentriq, Phesgo |
| Array Biopharma INC | $41.84 | 2025 | Mektovi, Braftovi, Lorbrena |
| Eisai INC. | $41.56 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $37.02 | 2025 | Fruzaqla |
| Beone Medicines USA, INC. | $34.41 | 2025 | Brukinsa |
| Tersera Therapeutics LLC | $33.68 | 2025 | Quzyttir |
| Lilly USA, LLC | $28.67 | 2025 | Jaypirca, Retevmo, Verzenio |
| Sumitomo Pharma America, INC. | $28.41 | 2025 | Orgovyx |
| Pharmaessentia USA Corporation | $27.76 | 2025 | Besremi |
| Recordati_rare_diseases_inc. | $25.08 | 2025 | Enjaymo |
| Jazz Pharmaceuticals INC. | $25.01 | 2025 | |
| Puma Biotechnology, INC. | $24.92 | 2025 | |
| Azurity Pharmaceuticals, INC. | $23.17 | 2025 | Danziten |
| Genzyme Corporation | $22.44 | 2025 | |
| Incyte Corporation | $21.81 | 2025 | Jakafi |
| Emd Serono, INC. | $19.92 | 2025 | |
| Alexion Pharmaceuticals, INC. | $19.54 | 2025 | Ultomiris |
| Servier Pharmaceuticals LLC | $18.97 | 2025 | |
| Pfizer INC. | $16.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shiny Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.